 | Related Articles |
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Colomb Med (Cali). 2016 Dec 30;47(4):203-212
Authors: Barrera-Ocampo A, Lopera F
Abstract
Alzheimer disease (AD) is the most prevalent form of dementia of adult-onset, characterized by progressive impairment in cognition and memory. There is no cure for the disease and the current treatments are only symptomatic. Drug discovery is an expensive and time-consuming process; in the last decade no new drugs have been found for AD despite the efforts of the scientific community and pharmaceutical companies. The Aβ immunotherapy is one of the most promising approaches to modify the course of AD. This therapeutic strategy uses synthetic peptides or monoclonal antibodies (mAb) to decrease the Aβ load in the brain and slow the progression of the disease. Therefore, this article will discuss the main aspects of AD neuropathogenesis, the classical pharmacologic treatment, as well as the active and passive immunization describing drug prototypes evaluated in different clinical trials.
PMID: 28293044 [PubMed - in process]
http://ift.tt/2mrwU0w
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου